Comparing Azenta (AZTA) & Its Rivals

Azenta (NASDAQ:AZTA – Get Free Report) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it compare to its rivals? We will compare Azenta to similar companies based on the strength of its dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Azenta and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Azenta -26.86% 1.41% 1.15%
Azenta Competitors -487.63% 79.17% -12.95%

Analyst Recommendations

This is a summary of current ratings and price targets for Azenta and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Azenta 1 2 4 0 2.43
Azenta Competitors 957 3193 5531 179 2.50

Azenta presently has a consensus target price of $47.60, indicating a potential upside of 5.97%. As a group, “Life Sciences Tools & Services” companies have a potential upside of 1.08%. Given Azenta’s higher probable upside, equities analysts clearly believe Azenta is more favorable than its rivals.

Insider and Institutional Ownership

99.1% of Azenta shares are owned by institutional investors. Comparatively, 54.0% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 10.9% of Azenta shares are owned by insiders. Comparatively, 14.8% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Azenta has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Azenta’s rivals have a beta of 0.93, suggesting that their average share price is 7% less volatile than the S&P 500.

Valuation & Earnings

This table compares Azenta and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Azenta $621.70 million -$166.99 million -12.41
Azenta Competitors $2.33 billion $55.11 billion -7.62

Azenta’s rivals have higher revenue and earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Dividends

Azenta pays an annual dividend of $0.10 per share and has a dividend yield of 0.2%. Azenta pays out -2.8% of its earnings in the form of a dividend. As a group, “Life Sciences Tools & Services” companies pay a dividend yield of 8.1% and pay out 45.1% of their earnings in the form of a dividend.

Summary

Azenta rivals beat Azenta on 8 of the 15 factors compared.

Azenta Company Profile

(Get Free Report)

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.

Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.